Prelude TherapeuticsPRLD +1.63%26 Market Cap is $397.43 Mil as of Jul. 07, 2026. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 1,422 Biotechnology companies, Prelude Therapeutics ranks better than 67.16% on this metric.
Prelude Therapeutics's quarterly market cap
increased
from Sep. 2025 ($81.50 Mil) to Dec. 2025 ($182.57 Mil) and
increased
from Dec. 2025 ($182.57 Mil) to Mar. 2026 ($215.52 Mil).
Prelude Therapeutics's annual market cap
declined
from Dec. 2023 ($234.48 Mil) to Dec. 2024 ($70.31 Mil) but then
increased
from Dec. 2024 ($70.31 Mil) to Dec. 2025 ($182.57 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Prelude Therapeutics's Enterprise Value for Today is $333.60 Mil.
Prelude Therapeutics (NAS:PRLD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Prelude Therapeutics Market Cap Related Terms
Prelude Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Prelude Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prelude Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prelude Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Prelude Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Prelude Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prelude Therapeutics (PRLD) has a Market Cap of $397.43 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Prelude Therapeutics and its competitors. According to the industry distribution chart, Prelude Therapeutics ranks #467 out of 1422 companies in the Biotechnology industry, placing it in the top 32.8%.
Is Prelude Therapeutics' Market Cap too high?
Prelude Therapeutics' current Market Cap is $397.43 Mil. The Biotechnology industry median Market Cap is 120.73. Prelude Therapeutics' value of $397.43 Mil is 229.2% above this industry median. Based on the distribution chart, Prelude Therapeutics ranks #467 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Market Cap compare to DMAC and RCKT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #467 out of 1422 companies for Market Cap. This puts Prelude Therapeutics in the upper half of its industry. The industry median Market Cap is 120.73. Prelude Therapeutics' value of $397.43 Mil is 229.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.73, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prelude Therapeutics's current Market Cap of $397.43 Mil is 229.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Prelude Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 120.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prelude Therapeutics's current Market Cap is $397.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Market Cap of $397.43 Mil. The current Market Cap is $397.43 Mil and 229.2% above the Biotechnology industry median of 120.73. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Market Cap is $397.43 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score
Get the complete analysis for PRLD
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRLD has been successfully added to your 
